Sun Pharma Advanced Research Co. Ltd. (IN:SPARC)
:SPARC
Want to see IN:SPARC full AI Analyst Report?
SPARC Stock Chart & Stats
₹135.70
-₹2.58(-1.32%)
At close: 4:00 PM EST
₹135.70
-₹2.58(-1.32%)
Day’s Range― - ―
52-Week Range₹108.20 - ₹248.65
Previous CloseN/A
Volume383.41K
Average Volume (3M)24.00K
Market Cap
₹67.55B
Enterprise Value₹74.42B
Total Cash (Recent Filing)₹30.00M
Total Debt (Recent Filing)₹4.17B
Price to Earnings (P/E)4.5
Beta1.75
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.23
Shares Outstanding324,521,580
10 Day Avg. Volume27,089
30 Day Avg. Volume24,005
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.78
Price to Sales (P/S)1.98
P/FCF Ratio-12.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Successful FY2026 Revenue ReboundA large, durable step-up in reported revenue and profitability indicates the company can generate significant commercial or milestone-related receipts when programs progress. If sustained, this improves partner confidence, funding optionality, and ability to reinvest in R&D over the medium term.
Improved Leverage And Balance-sheet CapacityManageable debt-to-equity (~0.42) and larger asset base in FY2026 provide the firm with capacity to finance clinical programs or secure partner deals without immediate distress. Stronger balance-sheet capacity supports multi-stage R&D funding and reduces short-term refinancing risk.
Partnership / Out-licensing Business ModelA capital-efficient model focused on out-licensing, milestone payments and royalties shares development risk with partners and creates long-term, scalable royalty streams if successful. This model aligns incentives, lowers standalone commercialization burden and can stabilize cash flows over time.
Bears Say
Persistent Negative Operating Cash FlowConsistent cash burn despite reported profits undermines earnings quality and creates ongoing funding needs. Over a multi-month horizon this raises refinancing or dilution risk, constrains ability to self-fund trials, and makes long-term R&D plans dependent on partner payments or new capital.
Volatile Multi-year Profitability And EquityA history of large swings—multi-year losses, negative margins, and episodes of negative equity—signals unstable earnings and balance-sheet resilience. This volatility increases the probability that future program setbacks could force asset sales, restructurings, or expensive capital raises.
Earnings Quality And Funding RiskMaterial divergence between reported profits and cash generation implies earnings may include one-off items or non-cash gains. Persistent funding risk can limit strategic flexibility, delay program timelines, and heighten dependency on partner milestone payments, impacting long-term execution reliability.
Sun Pharma Advanced Research Co. Ltd. News
SPARC FAQ
What was Sun Pharma Advanced Research Co. Ltd.’s price range in the past 12 months?
Sun Pharma Advanced Research Co. Ltd. lowest stock price was ₹108.20 and its highest was ₹248.65 in the past 12 months.
What is Sun Pharma Advanced Research Co. Ltd.’s market cap?
Sun Pharma Advanced Research Co. Ltd.’s market cap is ₹67.55B.
When is Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date?
Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date is Aug 10, 2026 which is in 65 days.
How were Sun Pharma Advanced Research Co. Ltd.’s earnings last quarter?
Sun Pharma Advanced Research Co. Ltd. released its earnings results on May 18, 2026. The company reported ₹54.27 earnings per share for the quarter, beating the consensus estimate of N/A by ₹54.27.
Is Sun Pharma Advanced Research Co. Ltd. overvalued?
According to Wall Street analysts Sun Pharma Advanced Research Co. Ltd.’s price is currently Overvalued.
Does Sun Pharma Advanced Research Co. Ltd. pay dividends?
Sun Pharma Advanced Research Co. Ltd. does not currently pay dividends.
What is Sun Pharma Advanced Research Co. Ltd.’s EPS estimate?
Sun Pharma Advanced Research Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sun Pharma Advanced Research Co. Ltd. have?
Sun Pharma Advanced Research Co. Ltd. has 324,521,580 shares outstanding.
What happened to Sun Pharma Advanced Research Co. Ltd.’s price movement after its last earnings report?
Sun Pharma Advanced Research Co. Ltd. reported an EPS of ₹54.27 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.886%.
Which hedge fund is a major shareholder of Sun Pharma Advanced Research Co. Ltd.?
Currently, no hedge funds are holding shares in IN:SPARC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sun Pharma Advanced Research Co. Ltd.
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited
Technical Analysis
Jubilant Pharmova Limited
―
Neuland Laboratories Ltd.
―
Piramal Pharma Limited
―
Suven Life Sciences Limited
―
Suven Pharmaceuticals Ltd.
―